Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019029295) PAZOPANIB-BASED HDAC AND VEGFR DOUBLE-TARGET INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/029295 International Application No.: PCT/CN2018/093968
Publication Date: 14.02.2019 International Filing Date: 02.07.2018
IPC:
C07D 403/12 (2006.01) ,A61K 31/506 (2006.01) ,A61P 35/00 (2006.01) ,A61P 35/02 (2006.01) ,C07D 239/48 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
239
Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02
not condensed with other rings
24
having three or more double bonds between ring members or between ring members and non-ring members
28
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46
Two or more oxygen, sulfur or nitrogen atoms
48
Two nitrogen atoms
Applicants:
山东大学 SHANDONG UNIVERSITY [CN/CN]; 中国山东省济南市 历城区山大南路27号 No.27 Shanda Nan Rd., Licheng District Jinan, Shandong 250199, CN
Inventors:
张颖杰 ZHANG, Yingjie; CN
徐文方 XU, Wenfang; CN
臧杰 ZANG, Jie; CN
Agent:
济南金迪知识产权代理有限公司 JINAN JINDI INTELLECTUAL PROPERTY AGENCY CO., LTD.; 中国山东省济南市 历城区山大南路29号山大鲁能科技大厦A座四楼410室 Room 410, Block A, Shanda Luneng Technology Building, No. 29 Shanda South Road, Licheng District Jinan, Shandong 250199, CN
Priority Data:
201710677980.210.08.2017CN
Title (EN) PAZOPANIB-BASED HDAC AND VEGFR DOUBLE-TARGET INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
(FR) INHIBITEUR DOUBLE CIBLE POUR HDAC ET VEGFR SUIVANT LA STRUCTURE DU PAZOPANIB, SON PROCÉDÉ DE PRÉPARATION ET SON APPLICATION
(ZH) 基于帕唑帕尼结构的HDAC和VEGFR双靶点抑制剂及其制备方法和应用
Abstract:
(EN) The present invention relates to a pazopanib-based HDAC and VEGFR double-target inhibitor, a preparation method therefor and an application thereof. Said compound has a structure as presented in formula I, II or III. The present invention also relates to a preparation method for this type of compound and the application thereof in preparing drugs for treating or preventing oncological diseases.
(FR) L'invention concerne un inhibiteur double cible pour HDAC et VEGFR suivant la structure du pazopanib, son procédé de préparation et son application. Ledit composé adopte la structure de la formule I, II ou III. La présente invention concerne également un procédé de préparation de ce type de composé et son application dans la préparation ou la prévention de maladies oncologiques.
(ZH) 本发明涉及基于帕唑帕尼结构的HDAC和VEGFR双靶点抑制剂及其制备方法和应用。所述化合物具有通式I、II或III所示的结构。本发明还提供该类化合物的制备方法以及在制备预防或治疗与肿瘤相关疾病药物中的应用。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)